Prognostic Value of LRG1 in Breast Cancer: A Retrospective Study
Oncology Research and Treatment · 2021 · 44 (1-2) · 36-42
DOI: 10.1159/000510945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 26.11.2020. Verfasst von Yan-Shou Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
High expression of leucine-rich alpha-2-glycoprotein 1 (LRG1) is closely related to angiogenesis, which may play an important role in promoting invasion and metastasis. However, the current literature has yet to clarify the clinical significance of LRG1 in breast cancer.
Objectives
The purpose of this work was to validate the correlation between LRG1 expression and prognosis in early breast cancer.
Methods
We utilized an LRG1 detection agent in 330 cases of early breast cancer. The correlation of LRG1 expression with clinicopathological features, patient recurrence, and survival was investigated.
Results
Compared with adjacent tissue samples, an elevated expression of LRG1 was observed in breast cancer samples. Moreover, LRG1 expression is associated with the number of lymphatic metastases and TNM pathological stage (p = 0.000, p = 0.000, respectively). For disease-free survival (DFS), the Kaplan-Meier curve indicated a poorer prognosis for the group with high LRG1 levels compared with the low LRG1 group (p = 0.000). A similar result was found for overall survival (OS; p = 0.000). The multivariate Cox regression indicated that LRG1 was still associated with DFS (HR 2.090, 95% CI 1.205–3.625, p = 0.009) and OS (HR 2.112, 95% CI 1.167–3.822, p = 0.013). The histological grade, TNM pathological stage, and molecular subtype were identified as independent risk factors affecting OS.
Conclusion
In the malignant progression of breast cancer, high LRG1 levels are associated with lymphatic metastasis, histological grade, poor DFS, and poor OS. This study validates the use of LRG1 as a potential prognosis biomarker for early breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Cancer Center, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China.
- Department of Radiotherapy, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China.
- Breast Cancer Center, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China, lyj818326@outlook.com.
- Research Center, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China.
Zitieren
APA
Zhang, Y. S., Han, L., Yang, C., Liu, Y. J., & Zhang, X. M. (2021). Prognostic Value of LRG1 in Breast Cancer: A Retrospective Study. Oncology Research and Treatment, 44(1-2), 36-42. https://doi.org/10.1159/000510945
Vancouver
Zhang YS, Han L, Yang C, Liu YJ, Zhang XM. Prognostic Value of LRG1 in Breast Cancer: A Retrospective Study. Oncology Research and Treatment. 2021;44(1-2):36-42. doi:10.1159/000510945
BibTeX
@article{Zhang2021,
author = {Zhang, Yan-Shou and Han, Lei and Yang, Chao and Liu, Yun-Jiang and Zhang, Xiang-Mei},
title = {Prognostic Value of LRG1 in Breast Cancer: A Retrospective Study},
journal = {Oncology Research and Treatment},
year = {2021},
volume = {44},
number = {1-2},
pages = {36--42},
doi = {10.1159/000510945}
}
EUVIMED